Mantle cell lymphoma
Mantle cell lymphoma Classification and external resources
Micrograph showing mantle cell lymphoma (bottom of image) in a biopsy of the terminal ileum. H&E stain.
ICD-10 C85.7 ICD-9 200.4 ICD-O: M9673/3 eMedicine med/1361 MeSH D020522
Mantle cell lymphoma (MCL) is one of the rarest of the non-Hodgkin's lymphomas (NHLs), comprising about 6% of NHL cases. There are only about 15,000 patients presently in the U.S. (The prevalence seems to be somewhat higher in Europe.) While it is difficult to treat and seldom considered cured, investigations into better treatments are actively pursued worldwide. Median survival times were about 3 years, but are now estimated as approaching 6 years for new patients.
MCL is a subtype of B-cell lymphoma, due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles. MCL cells generally over-express cyclin D1 due to a t(11:14) chromosomal translocation in the DNA. More specifically, the translocation is at t(11;14)(q13;q32).
The cause is unknown and no inherited predisposition has been identified. MCL is not communicable. It essentially is an abnormal break and subsequent translocation in a gene that causes the cells to divide too early before becoming capable of helping to fight diseases. In addition, the cells do not die as they should and therefore accumulate in the lymphoid system, including lymph nodes and the spleen, with non-useful cells eventually rendering the system dysfunctional. MCL affected cells proliferate in a nodular or diffuse pattern with two main cytologic variants: typical or blastic. Typical cases are small to intermediate sized cells with irregular nuclei. Blastic (aka blastoid) variants have intermediate to large sized cells with finely dispersed chromatin and are more aggressive in nature.
The ratio of males to females affected is about 4:1. At diagnosis, typical patients are in their 60s and usually present to the oncologist with advanced disease. About half have either fever, heavy night sweats, unexplained weight loss (over 10%) or some combination. Swelling of lymph nodes and spleen are usually present. Bone marrow, liver and GI tract involvement occurs in a very high percentage.
It is common for a person to have initially noticed "a bump" on the neck or in the armpits or groin.
Diagnosis generally requires stained slides of a surgically removed part of a lymph node. Other methods are also commonly used, including cytogenetics and fluorescence in situ hybridization (FISH). Polymerase chain reaction (PCR) and CER3 clonotypic primers are additional methods, but are less often used.
The immunophenotype profile consists of CD5+ (in about 80%), CD10-/+,It is usually CD5+ and CD10-. CD20+, CD23-/+ (though plus in rare cases). Generally cyclin D1 is expressed but it may not be required. The workup for Mantle cell lymphoma is similar to the workup for many indolent lymphomas and certain aggressive lymphomas.
Mantle cell lymphoma is a systemic disease with frequent involvement of the bone marrow and gastrointestinal tract (generally showing polyposis in the lining). There is also a not-uncommon leukemic phase, marked by presence in the blood. For this reason, both the peripheral blood and bone marrow are evaluated for the presence of malignant cells. Chest, abdominal, and pelvic CT scans are routinely performed.
Since mantle cell lymphoma may present a lymphomatous polyposis coli and colon involvement is common, colonoscopy is now considered a routine part of the evaluation. Upper endoscopy and neck CT scan may be helpful in selected cases. In some patients with the blastic variant, lumbar puncture is done to evaluate the spinal fluid for involvement.
Attempts to determine causes of MCL have failed. It is not known what causes the translocation damage to the gene. Exposure to toxins is often mentioned as a possibility. The translocation damage to a gene is required in only one cell for the cancer to begin.
Prognosis for individuals with MCL is problematic and indexes do not work as well due to patients presenting with advanced stage disease. Staging is used but is not very informative, since the malignant B-cells can travel freely though the lymphatic system and therefore most patients are at stage III or IV at diagnosis. Prognosis is not strongly affected by staging in MCL and the concept of metastasis does not really apply.
The Mantle Cell Lymphoma International Prognostic Index (MIPI) was derived from a data set of 455 advanced stage MCL patients treated in series of clinical trials in Germany/Europe. Of the evaluable population, approximately 18% were treated with high-dose therapy and stem cell transplantation in first remission. The MIPI is able to classify patients into three risk groups: low risk (median survival not reached after median 32 mos follow-up and 5-year OS rate of 60%), intermediate risk (median survival 51 months) and high risk (median survival 29 months). In addition to the 4 independent prognostic factors included in the model, the cell proliferation index (Ki-67) was also shown to have additional prognostic relevance. When the Ki67 is available, a biologic MIPI can be calculated.
(The letter A after the Roman numeral indicates that normal external symptoms are not present. The Letter B indicates the symptoms are present and hence they are called “B Symptoms”.)
MCL is one of the few NHLs that can cross the boundary into the brain, yet it can be treated in that event.
There are a number of prognostic indicators that have been studied. There is not universal agreement on their importance or usefulness in prognosis.
Ki-67 is an indicator of how fast cells mature and is expressed in a range from about 10% to 90%. The lower the percentage, the lower the speed of maturity, and the more indolent the disease. Katzenberger et al. Blood 2006;107:3407 graphs survival versus time for subsets of patients with varying Ki-67 indices. He shows median survival times of about one year for 61-90% Ki-67 and nearly 4 years for 5-20% Ki-67 index.
MCL cell types can aid in prognosis in a subjective way. Blastic is a larger cell type. Diffuse is spread through the node. Nodular are small groups of collected cells spread through the node. Diffuse and nodular are similar in behavior. Blastic is faster growing and it is harder to get long remissions. Some thought is that given a long time, some non-blastic MCL transforms to blastic. Although survival of most blastic patients is shorter, some data shows that 25% of blastic MCL patients survive to 5 years. That is longer than diffuse type and almost as long as nodular (almost 7 yrs).
Beta-2 microglobulin is another risk factor in MCL used primarily for transplant patients. Values less than 3 have yielded 95% overall survival to 6 yrs for auto SCT where over 3 yields a median of 44 mos overall survival for auto SCT (Khouri 03). This is not yet fully validated.
Testing for high levels of LDH in NHL patients is useful because LDH is released when body tissues break down for any reason. While it cannot be used as a sole means of diagnosing NHL, it is a surrogate for tracking tumor burden in those diagnosed by other means. The normal range is approximately 100-190.
Key diagnostics for MCL
- CT Scan - Computerized tomography scan yields images of part or whole body. Gives a large number of slices on X-ray image.
- PET Scan - Generally of the whole body, shows a three-dimensional image of where previously injected radioactive glucose is metabolized at a rapid rate. Faster-than-average metabolism shows as a black area and indicates that cancer is likely present. Metabolism of radioactive glucose may give a false positive, particularly if the patient has exercised before the test.
PET scans are much more effective when the information from them is integrated with that from a CT scan to show more precisely where the cancer activity is located and to more accurately measure the size of tumors.
There are no proven standards of treatment for MCL, and not even consensus among specialists on how to treat it optimally. Many regimens are available and often get good response rates, but patients almost always get disease progression after chemotherapy. Each relapse is typically more difficult to treat, and relapse is generally faster. Fortunately, regimens are available that will treat relapse, and new approaches are under test. Because of the aforementioned factors, many MCL patients enroll in clinical trials to get the latest treatments.
There are four classes of treatments currently in general use: chemotherapy, immune based therapy, radioimmunotherapy and new biologic agents. The phases of treatment are generally: frontline, following diagnosis, consolidation, after frontline response (to prolong remissions), and relapse. Relapse is usually experienced multiple times.
Chemotherapy is widely used as frontline treatment, and often is not repeated in relapse due to side effects. Alternate chemotherapy is sometimes used at first relapse. For frontline treatment, CHOP with rituximab (Rituxan, Mabthera) is the most common chemotherapy, and often given as outpatient by IV. A stronger chemotherapy with greater side effects (mostly hematologic) is HyperCVAD, often given as in-patient, with rituximab and generally to fitter patients (some of which are over 65). HyperCVAD is becoming popular and showing promising results, especially with rituximab. It can be used on some elderly (over 65) patients, but seems only beneficial when the baseline Beta-2-MG blood test was normal. It is showing better complete remissions (CR) and progression free survival (PFS) than CHOP regimens. Another chemotherapy class is fludarabine monotherapy, sometimes combined with cyclophosphamide and mitoxantrone, usually with rituximab. Cladribine and clofarabine are two other drugs being investigated in MCL. Cytotoxic chemotherapies, including bendamustin, are being studied alone and with similar combinations. A relatively new regimen that uses old drugs is PEP-C, which includes relatively small, daily doses of prednisone, etoposide, procarbazine, and cyclophosphamide, taken orally, has proven effective for relapsed patients. According to John Leonard M.D., a key researcher/proponent of PEP-C, may have anti-angiogenetic properties, something that he and his colleagues are testing through an ongoing drug trial.
Another approach involves using very high doses of chemotherapy, sometimes combined with total body irradiation (TBI), in an attempt to destroy all evidence of the disease. The downside to this is the destruction of the patients' entire immune system as well, requiring rescue by transplantation of a new immune system (Hematopoietic stem cell transplantation), using either ones' own previously treated and stored stem cells (an autologous stem cell transplant), or those from a matched donor (an allogeneic stem cell transplant). A presentation at the December 2007 American Society of Hematology (ASH) conference by Christian Geisler, chairman of the Nordic Lymphoma Group (Copenhagen, Denmark), claimed that according to trial results, mantle cell lymphoma is potentially curable with very intensive chemo-immunotherapy followed by a stem cell transplant, when treated upon first presentation of the disease.
Immune-based therapy is dominated now by the oft used and effective rituximab monoclonal antibody, sold under the trade name Rituxan (or as Mabthera in Europe and Australia). Some say it is a landmark medicine. It can have good activity against MCL alone but especially in combination with chemotherapies to prolong response duration. Rituximab essentially tags the cancer cells for destruction by the body. There are newer variations on monoclonal antibodies combined with radioactive molecules known as Radioimmunotherapy (RIT). These include Zevalin and Bexxar. Rituximab has also been used in small numbers of patients in combination with thalidomide with some effect.
It will be fruitful to investigate the use of Bexxar as first line treatment. This treatment appears to be less tiring for patients, since it consists of two injections at a distance of a week, while most other treatments consist of 6-8 cycles of chemotherapy combined with Rituximab.
In contrast to these antibody-based 'passive' immunotherapies, the field of 'active' immunotherapy tries to reprogram a patient's immune system to specifically recognize and eliminate their own tumor cells. Examples of active immunotherapy include cancer vaccines, adoptive cell transfer, and immunotransplant, which combines vaccination and autologous stem cell transplant. Though no active immunotherapies are currently a standard of care, numerous clinical trials are ongoing.
New targeted agents include the proteasome inhibitor Velcade and mTor inhibitors such as temsirolimus.
- List of hematologic conditions
- ^ Mantle Cell Lymphoma
- ^ t(11;14)(q13;q32)
- ^ Li JY, Gaillard F, Moreau A, et al. (May 1999). "Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization". Am. J. Pathol. 154 (5): 1449–52. doi:10.1016/S0002-9440(10)65399-0. PMC 1866594. PMID 10329598. http://ajp.amjpathol.org/cgi/pmidlookup?view=long&pmid=10329598.
- ^ Barouk-Simonet E, Andrieux J, Copin MC, et al. (2002). "TPA stimulation culture for improved detection of t(11;14)(q13;q32) in mantle cell lymphoma". Ann. Genet. 45 (3): 165–8. doi:10.1016/S0003-3995(02)01122-X. PMID 12381451. http://linkinghub.elsevier.com/retrieve/pii/S000339950201122X.
- ^ Mantle Cell Lymphoma: An Update for Clinicians
- ^ Stanford School of Medicine: "Mantle Cell Lymphoma, Differential Diagnosis" 
- ^ Barekman CL, Aguilera NS, Abbondanzo SL (July 2001). "Low-grade B-cell lymphoma with coexpression of both CD5 and CD10. A report of 3 cases". Arch. Pathol. Lab. Med. 125 (7): 951–3. doi:10.1043/0003-9985(2001)125<0951:LGBCLW>2.0.CO;2. PMID 11419985. http://journals.allenpress.com/jrnlserv/?request=get-abstract&issn=0003-9985&volume=125&page=951.
- ^ Most recent values in: Herrmann A, Hoster E, Zwingers T, et al. (February 2009). "Improvement of overall survival in advanced stage mantle cell lymphoma". J. Clin. Oncol. 27 (4): 511–8. doi:10.1200/JCO.2008.16.8435. PMID 19075279.
- ^ Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM (October 2003). "Limited-stage mantle-cell lymphoma". Ann. Oncol. 14 (10): 1555–61. doi:10.1093/annonc/mdg414. PMID 14504058.
- ^ Hoster et al. (2008). "A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma". Blood 111 (2): 558–565. doi:10.1182/blood-2007-06-095331. PMID 17962512.
- ^ http://www.asco.org/ASCO/Abstracts+&+Virtual+Meeting/Abstracts?&vmview=abst_detail_view&confID=23&abstractID=104642
- ^ http://www.mantlecelllymphoma.org/default.asp?pgid=122
- ^ http://clinicaltrials.gov/ct2/show/NCT00151281?cond=%22Lymphoma%2C+Mantle-Cell%22&rank=55
- ^ http://www.nordic-lymphoma.org/mcl2eng.htm
- ^ http://www.docguide.com/news/content.nsf/news/852571020057CCF6852573AD006260EB?OpenDocument&id=48DDE4A73E09A969852568880078C249&c=Lymphomas&count=10
- ^ http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_6026&terms=
- ^ Kaufmann, Hannes; Markus Raderer, Stefan Wöhrer, Andreas Püspök, Alexander Bankier, Christoph Zielinski, Andreas Chott, Johannes Drach (15 October 2004). "Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma" (PDF). Blood 104 (8): 2269–71. doi:10.1182/blood-2004-03-1091. PMID 15166030. http://bloodjournal.hematologylibrary.org/cgi/reprint/104/8/2269. Retrieved 2008-02-13.
- ^ NCT00101101
- ^ NCT00020215
- ^ http://media.asco.org/player/flashplayer/player.aspx?LectureID=59241&conferenceFolder=am2011&SessionFolder=6619&configFile=config_akamai.xml&IMISID=67882&UserIP=220.127.116.11&cs=[vm_102_9_4106_59241__]
- ^ NCT00490529
- ^ Turgeon, Mary Louise (2005). Clinical hematology: theory and procedures. Hagerstown, MD: Lippincott Williams & Wilkins. pp. 283. ISBN 0-7817-5007-5. "Frequency of lymphoid neoplasms. (Source: Modified from WHO Blue Book on Tumour of Hematopoietic and Lymphoid Tissues. 2001, p. 2001.)"
- A Brief Review of the Biology and Pathophysiology of Mantle Cell Lymphoma
- Mantle Cell Lymphoma Consortium
- Oral combination chemotherapy with Pep-C (C3) for mantle cell lymphoma (MCL): Daily prednisone, etoposide, procarbazine and cyclophosphamide. ASCO, 2003
- Oral combination chemotherapy for refractory/relapsed lymphoma with the PEP-C (C3) regimen (daily prednisone, etoposide, procarbazine, cyclophosphamide): Low-dose continuous metronomic multidrug therapy. 2007 ASCO Annual Meeting
- Lymphoma Association – Specialist UK charity providing free information and support to patients, their families, friends and carers
- CME on MCL by Andre Goy, MD
- archived audiocasts at Leukemia & Lymphoma Society
Hematological malignancy/leukemia histology (ICD-O 9590–9989, C81–C96, 200–208)
Lymphoid/Lymphoproliferative, Lymphomas/Lymphoid leukemias (9590–9739, 9800–9839)By development/
markerALL (Precursor B acute lymphoblastic leukemia/lymphoma)CD5+CD22+see immunoproliferative immunoglobulin disordersBy infectionBy development/
CD30-: Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma · Pleomorphic T-cell lymphoma · Lymphomatoid papulosis type BCD30+: CD30+ cutaneous T-cell lymphoma · Secondary cutaneous CD30+ large cell lymphoma · Lymphomatoid papulosis type AOther peripheralBy infectionHTLV-1 (Adult T-cell leukemia/lymphoma)NK cell/
(most CD56)Aggressive NK-cell leukemia · Blastic NK cell lymphomaT or NKLymphoid+myeloid
Cutaneous lymphoid hyperplasiaCutaneous lymphoid hyperplasia with bandlike and perivascular patterns · Cutaneous lymphoid hyperplasia with nodular pattern · Jessner lymphocytic infiltrate of the skin Pathology: chromosome abnormalities (Q90–Q99 · 758) Autosomal1q21.1 deletion syndrome/1q21.1 duplication syndrome/TAR syndrome (1) · Wolf-Hirschhorn syndrome (4) · Cri du chat/Chromosome 5q deletion syndrome (5) · Williams syndrome (7) · Jacobsen syndrome (11) · Miller–Dieker syndrome/Smith–Magenis syndrome (17) · DiGeorge syndrome (22) · 22q13 deletion syndrome (22)
genomic imprinting (Angelman syndrome/Prader–Willi syndrome (15))Distal 18q-/Proximal 18q-
X/Y linked TranslocationsLymphoidMyeloidOther Other
Wikimedia Foundation. 2010.
Look at other dictionaries:
mantle cell lymphoma — mantle zone lymphoma a rare form of non Hodgkin lymphoma having a usually diffuse pattern with both small lymphocytes and small cleaved cells; it may be a subgroup of diffuse, small cleaved cell lymphoma. It mainly affects people over 50 years of … Medical dictionary
mantle cell lymphoma — An aggressive (fast growing) type of B cell non Hodgkin’s lymphoma that usually occurs in middle aged or older adults. It is marked by small to medium size cancer cells that may be in the lymph nodes, spleen, bone marrow, blood, and… … English dictionary of cancer terms
B-cell lymphoma — Classification and external resources Micrograph showing a large B cell lymphoma. Field stain. ICD 10 C … Wikipedia
Diffuse large B-cell lymphoma — Classification and external resources Micrograph of a diffuse large B cell lymphoma. Field stain. ICD O … Wikipedia
Cutaneous T-cell lymphoma — CTCL redirects here. For the book by Loren Pope, see Colleges That Change Lives. Cutaneous T cell lymphoma Classification and external resources Micrograph showing cutaneous T cell lymphoma … Wikipedia
Nodal marginal zone B cell lymphoma — Classification and external resources ICD 9 200.3 ICD O: M9699/3 Nodal marginal zone B cell lymph … Wikipedia
Marginal zone B-cell lymphoma — Classification and external resources ICD 9 200.3 ICD O: M9699/3 … Wikipedia
Lymphoma — This article is about lymphoma in humans. For the disease in dogs, cats, and ferrets, see lymphoma in animals. Lymphoma Classification and external resources Follicular lymphoma replacing a lymph node … Wikipedia
Mantle zone — Germinal centre Image labeled in German, but Mantel zone visible near center. The mantle zone (or just mantle) of a lymphatic nodule (or lymphatic follicle) is an outer ring of small lymphocytes surrounding a germinal center … Wikipedia
Lymphoma — Tumor of the lymphoid tissue. Diagnosis is by biopsy. Treatment may be chemotherapy, radiation, surgery, or medication, depending on the age of the patient and type of tumor. * * * Any neoplasm of lymphoid tissue; in general use, synonymous with… … Medical dictionary